Compare Quest Diagnostics Inc (DGX) vs Gogoro Inc (GGR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Gogoro Inc — how do they compare? Quest Diagnostics Inc trades at $237.51 (market cap $26.21B), while Gogoro Inc trades at $2.51 (market cap $52.19M). The key difference: Quest Diagnostics Inc is far larger — about 502.2× Gogoro Inc's market cap, and Quest Diagnostics Inc pays a 1.45% dividend while Gogoro Inc pays none. Which is the better fit depends on your goals.
| DGX | GGR | |
|---|---|---|
Market Cap | $26.21B | $52.19M |
Sector | Health | Technology |
52-Week High | $238.50 | $7.50 |
52-Week Low | $173.49 | $2.55 |
Enterprise Value | $31.97B | $354.63M |
Dividend Yield | 1.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.
The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.
GGR trades at $2.46, down 4.65% today, with a bearish technical signal despite oversold RSI readings. The company reported Q1 2026 revenue of $281.48M with negative net income of -$79.97M, though operating cash flow improved to $35.90M. Valuation metrics show low P/S (0.14) and P/B (0.45) ratios, but profitability remains weak with negative ROE (-50.38%) and net margins (-24.68%).
The outlook remains challenging with persistent losses and negative cash flow, though management highlights margin improvements and subscriber growth. Key risks include execution on profitability and competitive pressures. Analyst consensus is neutral (100% Hold), reflecting cautious sentiment amid ongoing turnaround efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Gogoro Inc
Gogoro is a global technology leader in battery-swapping ecosystems for electric two-wheelers. It provides smart, sustainable urban mobility solutions and manages an extensive network of battery stations.
Read more on GGR →
